Antifungal Susceptibility Profiles of Olorofim (Formerly F901318) and Currently Available Systemic Antifungals against Mold and Yeast Phases of Talaromyces marneffei

被引：18

作者：

Zhang, Jing ^{[1
]}

Liu, Hongfang ^{[2
]}

Xi, Liyan ^{[1
,2
]}

Chang, Yun C. ^{[3
]}

Kwon-Chung, Kyung J. ^{[3
]}

Seyedmousavi, Seyedmojtaba ^{[3
,4
]}

机构：

[1] Sun Yat Sen Univ, Dept Dermatol & Venerol, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China

[2] Southern Med Univ, Dept Dermatol, Dermatol Hosp, Guangzhou, Peoples R China

[3] NIAID, Mol Microbiol Sect, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

[4] NIH, Microbiol Serv, Dept Lab Med, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2021年 / 65卷 / 06期

基金：

美国国家卫生研究院;

关键词：

Talaromyces marneffei; olorofim; INFECTED PATIENTS;

D O I：

10.1128/AAC.00256-21

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

In vitro antifungal susceptibility profiling of 32 clinical and environmental Talaromyces marneffei isolates recovered from southern China was performed against olorofim and 7 other systemic antifungals, including amphotericin B, 5-flucytosine, posaconazole, voriconazole, caspofungin, and terbinafine, using CLSI methodology. In comparison, olorofim was the most active antifungal agent against both mold and yeast phases of all tested Talaromyces marneffei isolates, exhibiting an MIC range, MIC50, and MIC90 of 0.0005 to 0.002 mu g/ml, 0.0005 mu g/ml, and 0.0005 mu g/ml, respectively.

引用

页数：7